Ossiam Sells 549 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ossiam decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 33,524 shares of the medical research company’s stock after selling 549 shares during the quarter. Ossiam’s holdings in Edwards Lifesciences were worth $2,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter worth $610,895,000. Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $555,939,000. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $213,844,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of research analyst reports. Morgan Stanley raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Evercore ISI lowered their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $78.55.

Edwards Lifesciences Stock Performance

Shares of EW opened at $71.56 on Monday. The firm’s fifty day simple moving average is $71.31 and its two-hundred day simple moving average is $70.92. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $42.07 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock valued at $5,163,062 over the last ninety days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.